RCT | High-dose dexamethasone and oxygen support strategies in intensive care unit patients with severe COVID-19 acute hypoxemic respiratory failure.
6 Jul, 2022 | 11:51h | UTC
Commentary on Twitter
In this RCT, high-dose dexamethasone did not significantly improve the 60-day survival. The oxygenation strategy in initially non-intubated patients did not significantly modify the 28-day risk of invasive mechanical ventilation requirement. https://t.co/ZNajW2KBKR
— JAMA Internal Medicine (@JAMAInternalMed) July 5, 2022